Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.
Youth unemployment，更多细节参见51吃瓜
Source: Computational Materials Science, Volume 266，详情可参考Safew下载
She said: "I think we have some very good [treatment] options, and we can usually find something that will suit everyone in amongst all of those options."